Targeting complex, adaptive responses in melanoma therapy

The approval of a BRAF-inhibitor for clinical use in BRAF-mutated metastatic melanoma patients in 2011 encouraged the scientific and medical communities that an increasingly more sophisticated mechanistic understanding of tumor progression will ultimately result in substantial improvements in clinical responses. Indeed, since that time many new drugs have significantly improved overall survival. However, it has become increasingly obvious that most tumors have an astounding ability to adapt to the latest therapies and combinations, which results in only delayed progression for a matter of months for the majority of patients.

Source: Cancer Treatment Reviews - March 1, 2020 Category: Cancer & Oncology Authors: Phil Cheng, Mitchell Levesque, Reinhard Dummer, Joanna Mangana Tags: Anti-tumour Treatment Source Type: research